AENDO October 40/4

Mauras, Nelly, Valerie Quarmby, and Duane C. Bloedow. Pharmacokinetics of insulin-like growth factor I in hypopituitarism: correlation with binding proteins. Am. J. Physiol. 277 (Endocrinol. Metab. 40): E579–E584, 1999.—We investigated the pharmacokinetics of recombinant human insulin-like growth factor I (rhIGF-I) in growth hormone deficiency (GHD). Nine GHD adults [age 25 6 3 (SE) yr] received rhIGF-I (60 μg/kg sc) twice, 10 h apart, and blood was sampled over 24 h. IGF-I and free IGF-I concentrations increased, whereas IGF binding protein 3 (IGFBP-3) and acid labile subunit (ALS) were unchanged during treatment. There was no correlation between absorption or terminal half-life of IGF-I and IGFBP-3 or ALS, but negative correlations with IGF-I clearance (CL/F) and volume of distribution (V/F). Positive correlations between both IGFBP-3 and ALS and IGF-I maximal concentration (Cmax) and time of Cmax (Tmax) were observed. Compared with normal individuals studied similarly (using 80 μg/kg), GHD subjects showed a normal absorption half-life, a faster elimination half-life, lower Cmax, yet normal Tmax and V/F. In conclusion, GHD is associated with normal absorption and distribution of IGF-I yet faster elimination kinetics. Additionally, IGFBP-3 and ALS concentrations modulate the peak concentrations of IGF-I achieved and correlate reciprocally with its V/F and CL/F, underscoring the critical importance of binding proteins in modulating the bioavailability of IGF-I in vivo in humans.